Novel 2,3-dihydrobenzofuran-2-carboxylic acids: Highly potent and subtype-selective PPARα agonists with potent hypolipidemic activity

Journal of Medicinal Chemistry

Volumn 48, Issue 17, 2005, Pages 5589-5599

  Shi, Guo Q ^a   Dropinski, James F ^a   Zhang, Yong ^a   Santini, Conrad ^a   Sahoo, Soumya P ^a   Berger, Joel P ^a   MacNaul, Karen L ^a   Zhou, Gaochao ^a   Agrawal, Arun ^a   Alvaro, Raul ^a   Cai, Tian Quan ^a   Hernandez, Melba ^a   Wright, Samuel D ^a   Moller, David E ^a   Heck, James V ^a   Meinke, Peter T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 5 [3 [2 CHLORO 4 (TRIFLUOROMETHOXY)PHENOXY]PROPOXY] 2,3 DIHYDRO 1 BENZOFURAN 2 CARBOXYLIC ACID; 2,3 DIHYDROBENZOFURAN 2 CARBOXYLIC ACID DERIVATIVE; ANTILIPEMIC AGENT; CHOLESTEROL; FENOFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; SIMVASTATIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; DYSLIPIDEMIA; HAMSTER; MALE; NONHUMAN; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTILIPEMIC AGENTS; BENZOFURANS; CARBOXYLIC ACIDS; CHOLESTEROL; CRICETINAE; DOGS; HUMANS; HYPERLIPIDEMIAS; MALE; MESOCRICETUS; MOLECULAR CONFORMATION; PPAR ALPHA; RADIOLIGAND ASSAY; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRANS-ACTIVATION (GENETICS); TRIGLYCERIDES;

EID: 23944503264     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm050373g     Document Type: Article

References (35)

1. Gotto, A. M., Jr. Triglyceride as a risk factor for coronary artery disease. Am. J. Cardiol. 1998, 82, 22Q-25Q.
2. Anum, E. A.; Adera, T. Hypercholesterolemia and coronary heart disease in the elderly: a meta-analysis. Annals of Epidemiology 2004, 14, 705-701.
3. Chong, P. H.; Bachenheimer, B. S. Current, New and Future Treatments in Dyslipidaemia and Atherosclerosis. Drugs 2000, 60, 55-93.
4. Milionis, H. J.; Elisaf, M. S.; Mikhailidis, D. P. Treatment of Dyslipidaemias in Patients with Established Vascular Disease: A Revival of the Fibrates. Curr. Med. Res. Opin. 2000, 16, 21-32.
5. Schoonjans, K.; Staels, B.; Auwerx, J. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J. Lipid. Res. 1996, 37, 907-925.
6. Staels, B.; Auwerx, J. Role of PPAR in the Pharmacological Regulation of Lipoprotein Metabolism by Fibrates and Thiazolidinediones. Curr. Pharm. Des. 1997, 3, 1-14.
7. Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J. C. Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation 1998, 98, 2088-2093.
8. Willson, T.; Brown, P.; Sternbach, D.; Henke, B. The PPARs: From Orphan Receptors to Drug Discovery. J. Med. Chem. 2000, 43, 527-550.
9. Issemann, I.; Green, S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature 1990, 347, 645-650.
10. Forman, B. M.; Chen, J.; Evans, R. M. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors α and δ. Proc. Natl. Acad. Sci. U.S.A. 1997, 94, 4312-4317.
11. Hertz, R.; Bishara-Shieban, J.; Bar-Tana, J. Mode of Action of Peroxisome Proliferators as Hypolidemic Drugs, Suppression of Apolipoprotein C-III. J. Biol. Chem. 1995, 270, 13470-13475.
12. Staels, B.; Dallongeville, J.; Auwerx, J.; Schoonjans, K.; Leitersdorf, E.; Fruchart, J. Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism. Circulation 1998, 98, 2088-2093.
13. Marx, N.; Sukhova, G. K.; Collins, T.; Libby, P.; Plutzky, J. PPARα Activators Inhibit Cytokine-Induced Vascular Cell Adhesion Molecule-1 Expression in Human Endothelial. Cell. Circulation 1999, 99, 3125-3131.
14. Delerive, P.; De Bosscher, K.; Besnard, S.; Berghe, W. V.; Peters, J. M.; Gonzalez, F. J.; Fruchart, J.; Tedgui, A.; Haegeman, G.; Staels, B. Peroxisome Proliferator-Activated Receptor α Negatively Regulates the Vascular Inflammatory Gene Response by Negative Cross-talk with Transcription Factors NF-κB and AP-1. J. Biol. Chem. 1999, 274, 32048-32054.
15. Staels, B.; Koenig, K.; Habib, A.; Merval, R.; Lebret, M.; Torra, I. P.; Delerive, P.; Fadel Chinetti, A. G.; Fruchart, J.; Najib, J.; Maclouf, J.; Tedgui, A. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature 1998, 393, 790-793.
16. Fonceca, V. Effect of thiazolidinediones on body weight in patients with diabetes mellitus. Am. J. Med. 2003, 115, 42-48.
17. Brown, P. J.; Winegar, D. A.; Plunket, K. D.; Moore, L. B.; Lewis, M. C.; Wilson, J. G.; Sundseth, S. S.; Koble, C. S.; Wu, Z.; Chapman, J. M.; Lehmann, J. M.; Kliewer, S. A.; Willson, T. M. A Ureido-Thioisobutyric Acid (GW9578) Is a Subtype-Selective PPARα Agonist with Potent Lipid-Lowering Activity. J. Med. Chem. 1999, 42, 3785-3788.
18. Brown, P. J.; Stuart, L. W.; Hurley, K. P.; Lewis, M. C.; Winegar, D. A.; Wilson, J. G.; Wilkison, W. O.; Ittoop, O. R.; Willson, T. M. Identification of a Subtype Selective Human PPARα Agonist Through Parallel-Array Synthesis. Bioorg. Med. Chem. Lett. 2001, 11, 1225-1227.
19. Nomura, M.; Tanase, T.; Ide, T.; Tsunoda, M.; Suzuki, M.; Uchiki, H.; Murakami, K.; Miyachi, H. Design, Synthesis, and Evaluation of Substituted Phenylpropanoic Acid Derivatives as Human Peroxisome Proliferator Activated Receptor Activators. Discovery of Potent and Human Peroxiome Proliferator Activated Rceptor Subtype-Selective Activators. J. Med. Chem. 2003, 46, 3581-3599.
20. Xu, Y.; Mayhugh, D.; Saeed, A.; Wang, X.; Thompson, R. C.; Dominianni, S. J.; Kauffman, R. F.; Singh, J.; Bean, J. S.; Bensch, W. R.; Barr, R. W.; Osborne, J.; Montrose-Rafizadeh, C.; Zink, R. W.; Yumibe, N. P.; Huang, N.; Luffer-Atlas, D.; Rungta, D.; Maise, D. E.; Mantlo, N. B. Design and Synthesis of a Potent and Selective Triazolone-Based Peroxisome Proliferator-Activated Receptor Agonist. J. Med. Chem. 2003, 46, 5121-5124.
21. Desai, R. C.; Han, W.; Metzger, E. J.; Bergman, J. P.; Gratale, D. F.; MacNaul, K. L.; Berger, J. P.; Doebber, T. W.; Leung, K.; Moller, D. E. 5-Aryl thiazolidine-2,4-diones: discovery of PPAR dual α/γ agonists as antidiabetic agents. Bioorg. Med. Chem. Lett. 2003, 13, 2795-2798.
22. Koyama, H.; Boueres, J. K.; Han, W.; Metzger, E. J.; Bergman, J. P.; Gratale, D. F.; Miller, D. J.; Tolman, R. L.; MacNaul, K. L.; Berger, J. P. 5-Aryl thiazolidine-2,4-diones as selective PPARγ agonists. Bioorg. Med. Chem. Lett. 2003, 13, 1801-1804.
23. Adams, A. D.; Yuen, W.; Hu, Z.; Santini, C.; Jones, A. B.; MacNaul, K. L.; Berger, J. P.; Doebber, T. W.; Moller, D. E. Amphipathic 3-phenyl-7-propylbenzisoxazoles; human PPAR gamma, delta and alpha agonists. Bioorg. Med. Chem. Lett. 2003, 13, 931-935.
24. Koyama, H.; Boueres, J. K.; Miller, D. J.; Berger, J. P.; MacNaul, K.; Wang, P. R.; Ippolito, M. C.; Wright, S. D.; Agrawal, A. K.; Moller, D. E.; Sahoo, S. P. (2R)-2-Methylchromane-2-carboxylic acids: Discovery of Selective PPARα Agonists as Hypolipidemic Agents. Bioorg. Med. Chem. Lett. 2005, 13, in press.
25. Koyama, H.; Miller, D. J.; Boueres, J. K.; Desai, R. C.; Jones, A. B.; Berger, J. P.; MacNaul, K. L.; Kelly, L. J.; Doebber, T. W.; Wu, M. S.; Zhou, G.; Wang, P. R.; Ippolito, M. C.; Chao, Y. S.; Agrawal, A. K.; Franklin, R.; Heck, J. V.; Wright, S. D.; Moller, D. E.; Sahoo, S. P. (2R)-2-ethylchromane-2- carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as anti-hyperglycemic and hypolipidemic agents. J. Med. Chem. 2004, 47, 3255-3263.
26. Mayer, P.; Brunel, P.; Imbert, T. A New efficient synthesis of Efaroxan. Bioorg. Med. Chem. Lett. 1999, 9, 3021-3022.
27. Berger, J. P.; Petro, A. E.; Macnaul, K. L.; Kelly, L. J.; Zhang, B.; Richards, K.; Elbrecht, A.; Johnson, B. A.; Zhou, G.; Doebber, T. W.; Biswas, C.; Parikh, M.; Sharma, N.; Tanen, M. R.; Thompson, G. M.; Ventre, J.; Adams, A. D.; Mosley, R.; Surwit, R. S.; Moller, D. E. Distinct Properties and Advantages of a Novel Peroxisome Proliferator-Activated Protein γ Selective Modulator. Mol. Endocrinol. 2003, 17, 662-676.
28. Berger, J. P.; Leibowitz, M. D.; Doebber, T. W.; Elbrecht, A.; Zhang, B.; Zhou, G.; Biswas, C.; Cullinan, C. A.; Hayes, N. S.; Li, Y.; Tanen, M.; Ventre, J.; Wu, M.; Berger, G. D.; Mosley, R.; Marquis, R.; Santini, C.; Sahoo, S. P.; Tolman, R. L.; Smith, R. G.; Moller, D. E. Novel Peroxisome Proliferator- activated Receptor (PPAR) γ and PPAR δ Ligands Produce Distinct Biological Effects. J. Biol. Chem. 1999, 274, 6718.
29. Keller, H. J.; Devchand, P. R.; Perroud, M.; Wahli, W. PPARα structure-functional relationships derived from species-specific differences in responsiveness to hypolipidemic agents. Biol. Chem. Hoppe-Seyler 1997, 378, 651-655.
30. Lewis, D. F. V.; Jacobs, M. N.; Lake, B. G. Molecular modeling of the peroxisome proliferator-activated receptor R (PPARα) from human, rat and mouse, based on homology with the human PPARα crystal structure. Toxicol. in Vitro 2002, 16, 275-280.
31. Desai, R. et al (Merck Research Laborabories), Unpublished results.
32. Miyachi, H.; Nomura, M.; Tanase, T.; Suzuki, M.; Murakami, K.; Awano, K. Enantio-dependent Binding and Transactivation of Optically Active Phenylpropanoic Acid Derivatives at Human Peroxisome Proliferator-Activated Receptor Alpha. Bioorg. Med. Chem. Lett. 2002, 12, 333-335.
33. Cronet, P.; Peterson, J. F.; Folmer, R.; Blomberg; Sjoblom, K.; Karlsson, U.; Lindstedt, E.; Bamberg, K. Structure of the PPAR alpha and gamma ligand binding domain in complex with AZ242; ligand selectivity and agonist activation in the PPAR family. Structure 2001, 9, 699-706.
34. Nagasawa, M.; Ide, T.; Suzuki, M.; Tsunoda, M.; Akasaka, Y.; Okazaki, T.; Mochizuki, T.; Murakami, K. Pharmacological characterization of a human-specific peroxisome proliferater-activated receptor α (PPARα) agonist in dogs. Biochem. Pharmacol. 2004, 67, 2057-2069.
35. Chao, Y. S. et al (Merck Research Laboratories). Unpublished results.